A Comparative Study on Winterfield 2512-G61 and Winterfield-2512 IBDV Immune-complex Vaccines in Commercial Broiler Chickens

Eliwa, Mahmoud Galal El-Din; Talaat, Shaimaa; Tantawy, Laila; Abd El-Razik, Alaa; Sultan, Hesham

doi:10.21608/jcvr.2022.240926

A Comparative Study on Winterfield 2512-G61 and Winterfield-2512 IBDV Immune-complex Vaccines in Commercial Broiler Chickens

Document Type : Original Article

Authors

¹ Department of poultry diseases, Animal health research institute, Agriculture research center, Giza, Egypt.

² Department of Birds and Rabbits Medicine, Faculty of Veterinary Medicine, University of Sadat City, Menoufiya, Egypt

³ Department of Pathology, Animal Health Research Institute, P. O. Box 264, Dokki, Giza, Egypt

10.21608/jcvr.2022.240926

Abstract

Infectious bursal disease (IBD) is a very dangerous immunosuppressive disease affecting poultry production worldwide. The good vaccination program that can overcome the maternal derived antibodies (MDA) in young chicks is the main method to control this disease. In this study, the immunogenicity and protective efficacy of two IBDV immune-complex (ICX) vaccines were evaluated against challenge with very virulent IBDV. A total of 240-day-old commercial broiler chicks (Cobb-500) were divided into 3 groups (80 birds in each group). The first and second groups were vaccinated subcutaneously (s/c) on day-1 with Winterfield 2512-G61 and Winterfield-2512 ICX vaccines, respectively, the third group left as non-vaccinated control group and all groups were challenged on day-35 with vvIBDV local field isolate (GenBank accession no.KX646373), The protection assessment based on mortality rate, clinical signs, postmortem gross lesions, bursa to body weight ratio (BBR), seroconversion and mean severity index (MSI) of histopathological lesion scores was evaluated. The results revealed that both vaccines provide complete protection against mortality and clinical signs after challenge with vvIBDV. In addition, the partial protection against bursal atrophy, the (BBR) were (0.76, 0.95 and 1.27) versus (0.49, 0.56 and0.25) in Winterfield 2512-G61, Winterfield-2512 vaccinated and non-vaccinated groups before challenge and 7-days post-challenge, respectively. The results of this study indicate that the vaccination with Immune-complex vaccines can provide complete protection against mortality and clinical signs; they also provide partial protection against bursal atrophy and histopathological lesions and give adequate immune response against challenge with the Egyptian vvIBDV.

Main Subjects